Antimicrobial resistance and healthcare-associated infections drive a large $80bn market opportunity. The company leverages proven infection prevention technology, focuses on licensing, and expands global partnerships, especially in wound management.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.